Danish drugmaker Novo Nordisk has reduced the price of its popular weight-loss drug, Wegovy, by up to 37% from its launch price in India. This move is aimed at increasing its market share in the fast-growing Indian market for obesity treatments. The company's document sent to distributors shows the price...
Eli Lilly Heats Up Weight-Loss Drug Race in India
Eli Lilly has launched its Mounjaro Kwikpen injector in India, intensifying competition with Novo Nordisk’s Wegovy. The Kwikpen, approved in June by India’s drug regulator, offers six dose strengths ranging from 2.5 mg to 15 mg. Prices for a month’s supply are: Dose (mg) Price (INR) Price (USD) 2.5 ₹14,000...
Eli Lilly’s Mounjaro Sees Strong Start in India
Eli Lilly's diabetes and weight-loss drug, Mounjaro, has received a "positive" response in India, with the company now focusing on meeting the significant demand in the world's most populous country. Lilly launched Mounjaro in India in March, ahead of competitor Novo Nordisk, tapping into a market grappling with increasing rates...
India’s Biocon to Develop Weight Loss Biosimilar
Bangalore-based drugmaker Biocon, is developing its own version of Novo Nordisk's wildly popular weight-loss drug Wegovy in a bid to be a part of the exploding obesity treatment market that is forecast to reach at least $100 billion by 2030. The company's CEO Siddharth Mittal said they aim to be...
India’s Biocon Approved for the First Generic Version of liraglutide Injectible
Headquartered in Bangalore, Biocon Ltd, a leading Indian pharmaceutical company, is positioning itself in the weight loss drug market as patents for some blockbuster obesity medications are set to expire. The company has secured approval from the UK's regulatory authority for the first generic version of liraglutide, an injectable drug...